Summary & Overview
CPT 20983: Percutaneous Cryoablation of Metastatic Bone Tumor
CPT code 20983 designates percutaneous cryoablation of metastatic bone tumors, a minimally invasive procedure that uses an extremely cold probe to destroy bone lesions and adjacent soft tissue. Nationally, this code is important as cryoablation offers a palliative and sometimes curative option for patients with painful or progressive metastatic bone disease and is frequently billed in hospital outpatient departments, ambulatory surgical centers, and interventional radiology settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the procedure, typical sites of service, common billing considerations, and a summary of payer coverage patterns. The publication highlights benchmarks and coding practice notes relevant to payers listed above, and outlines areas where policy updates and utilization trends affect coding and billing workflows.
This national summary is intended to inform health plan analysts, revenue cycle professionals, and clinicians involved in procedural oncology and interventional radiology about coding expectations and the clinical circumstances under which CPT code 20983 is applied.
Billing Code Overview
CPT code 20983 describes percutaneous cryoablation of one or more metastatic bone tumors using cryo energy applied through the skin. The provider destroys the targeted bone lesion(s) and any adjacent involved soft tissues; imaging guidance may be used to identify and target diseased tissue and to visualize and control treatment during the procedure.
-
Service type: Percutaneous image‑assisted tumor ablation procedure
-
Typical site of service: Hospital outpatient setting or ambulatory surgical center; may also be performed in interventional radiology suites or specialized procedural suites depending on facility resources and imaging needs.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a history of metastatic solid tumor (for example, metastatic breast, lung, renal cell carcinoma) presenting with a symptomatic, radiographically confirmed metastatic bone lesion causing focal pain or at risk for local progression. The patient undergoes pre-procedure evaluation including review of oncologic history, cross-sectional imaging (CT or MRI) and, when indicated, PET to localize active disease. Multidisciplinary discussion occurs with medical oncology, radiation oncology and interventional radiology or orthopedic oncology to determine candidacy for percutaneous cryoablation.
On the day of service the patient is admitted to an outpatient interventional suite or hospital operating room depending on comorbidities and anesthesia needs. Conscious sedation or general anesthesia is administered. Imaging guidance (CT, fluoroscopy, or ultrasound) may be used to plan probe trajectory and monitor ice-ball formation. One or more cryoprobes are introduced percutaneously into the target lesion; cyclical freezing and thawing cycles are performed to achieve tumor necrosis and ablation of involved adjacent soft tissues as indicated. Post-procedure imaging documents ablation zone. The patient is monitored for immediate complications (bleeding, neurovascular injury) and discharged same day or admitted for observation based on clinical status and extent of procedure. Follow-up imaging is scheduled to assess local control and to coordinate additional systemic or local therapies as needed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |